Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ming-Huang Chen

Showing results (1-10 of 183) with videos related to

Pageof 19
Sort By:
Frontiers in Oncology|January 27, 2023
Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinibWen-Chi Wu, Ming-Huang Chen
International Journal of Molecular Sciences|January 27, 2019
mTOR Inhibitors in Advanced Biliary Tract CancersChao-En Wu, Ming-Huang Chen, Chun-Nan Yeh
Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi = Chinese Journal of Integrated Traditional and Western Medicine|May 12, 2012
[Effects of cucurmosin on the cell proliferation and apoptosis in human pancreatic PANC-1 cells]Chun-Sen Xu, He-Guang Huang, Ming-Huang Chen
Chinese Clinical Oncology|March 10, 2020
Targets for therapy in biliary tract cancers: the new horizon of personalized medicinePritish Iyer, Ming-Huang Chen, Lipika Goyal, et al.
Biomolecules|October 1, 2020
Omics-Based Platforms: Current Status and Potential Use for CholangiocarcinomaYu-Chan Chang, Ming-Huang Chen, Chun-Nan Yeh, et al.
Sensors (Basel, Switzerland)|October 17, 2020
Importing Automated Management System to Improve the Process Efficiency of Dental LaboratoriesCheng-Jung Yang, Ming-Huang Chen, Keng-Pei Lin, et al.
Biomolecules|January 16, 2021
Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical TrialsNai-Jung Chiang, Li-Tzong Chen, Yan-Shen Shan, et al.
Cancer Science|February 11, 2012
Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapyYao-Yu Hsieh, Cheng-Hwai Tzeng, Ming-Huang Chen, et al.
Zhongguo Shi Yan Xue Ye Xue Za Zhi|December 22, 2012
[Effects of cucurmosin combined with common chemotherapeutics on proliferation and apoptosis of NB4 cells]Jie-Ming Xle, Mei Liu, Ting-Bo Liu, et al.
Frontiers in Oncology|December 14, 2020
Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer TherapeuticsJiun-I Lai, Yu-Jhen Tseng, Ming-Huang Chen, et al.
Pageof 19

Showing results (1-10 of 183) with videos related to

Sort By:
Pageof 19
Frontiers in Oncology|January 27, 2023
Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinibWen-Chi Wu, Ming-Huang Chen
International Journal of Molecular Sciences|January 27, 2019
mTOR Inhibitors in Advanced Biliary Tract CancersChao-En Wu, Ming-Huang Chen, Chun-Nan Yeh
Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi = Chinese Journal of Integrated Traditional and Western Medicine|May 12, 2012
[Effects of cucurmosin on the cell proliferation and apoptosis in human pancreatic PANC-1 cells]Chun-Sen Xu, He-Guang Huang, Ming-Huang Chen
Chinese Clinical Oncology|March 10, 2020
Targets for therapy in biliary tract cancers: the new horizon of personalized medicinePritish Iyer, Ming-Huang Chen, Lipika Goyal, et al.
Biomolecules|October 1, 2020
Omics-Based Platforms: Current Status and Potential Use for CholangiocarcinomaYu-Chan Chang, Ming-Huang Chen, Chun-Nan Yeh, et al.
Sensors (Basel, Switzerland)|October 17, 2020
Importing Automated Management System to Improve the Process Efficiency of Dental LaboratoriesCheng-Jung Yang, Ming-Huang Chen, Keng-Pei Lin, et al.
Biomolecules|January 16, 2021
Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical TrialsNai-Jung Chiang, Li-Tzong Chen, Yan-Shen Shan, et al.
Cancer Science|February 11, 2012
Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapyYao-Yu Hsieh, Cheng-Hwai Tzeng, Ming-Huang Chen, et al.
Zhongguo Shi Yan Xue Ye Xue Za Zhi|December 22, 2012
[Effects of cucurmosin combined with common chemotherapeutics on proliferation and apoptosis of NB4 cells]Jie-Ming Xle, Mei Liu, Ting-Bo Liu, et al.
Frontiers in Oncology|December 14, 2020
Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer TherapeuticsJiun-I Lai, Yu-Jhen Tseng, Ming-Huang Chen, et al.
Pageof 19